Table 5.

Cytotoxicity activity of spiro-indoline derivatives 3a–c and 5a–l at different concentrations (0.0, 5.0, 12.5, 25 and 50 µg/mL) of some synthesized compounds and reference drug against human cancer cells line MCF7 breast cancer

CONC	DOX	3a	5a	5b	5c	5d	3b	5e	5f	5g	5h	3c	5i	5j	5k	5l
0.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
5.0	0.361	0.836	0.758	0.867	0.930	0.977	0.786	0.911	0.764	0.853	0.978	0.799	0.974	0.688	0.824	0.906
12.5	0.385	0.738	0.479	0.633	0.837	0.740	0.542	0.876	0.643	0.728	0.669	0.642	0.752	0.637	0.588	0.803
25.0	0.332	0.653	0.340	0.498	0.698	0.619	0.462	0.467	0.547	0.560	0.628	0.437	0.829	0.498	0.414	0.725
50.0	0.299	0.631	0.353	0.502	0.442	0.619	0.444	0.416	0.608	0.453	0.564	0.526	0.772	0.479	0.368	0.829
SD	0.024	0.009	0.013	0.025	0.020	0.016	0.034	0.039	0.120	0.022	0.020	0.025	0.010	0.013	0.058	0.009